SCHEMBL2369560

SCHEMBL2369560

CSc1nc(-c2ccc(NC(=O)NCCO)cc2)cc(-c2cc(F)ccc2SC)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
KDM4E B2RXH2 5/20 0.39
RAB9A P51151 3/20 0.39
GAA P10253 1/20 0.39
PDGFRB P09619 2/20 0.38
KDR P35968 2/20 0.38
FLT3 P36888 2/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
KCNH2 Q12809 1/20 0.38
HTR4 Q13639 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MOK Q9UQ07 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ATM Q13315 1/20 0.37
ABL1 P00519 3/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369938 0.76 KDM4E (0.41) LMNAKDM4ERAB9AGAAPDGFRB
SCHEMBL27911573 0.70 CNR1 (0.60) LMNAKDM4ERAB9AALDH1A1L3MBTL1
SCHEMBL2369679 0.69 PIK3CA (0.49) LMNAMOK
SCHEMBL2369758 0.67 ALOX5AP (0.37) MAPTLMNATP53THRBKDM4E
SCHEMBL5592977 0.67 ALDH1A1 (0.64) MAPTLMNATP53THRBKDM4E
SCHEMBL2369671 0.67 PIK3CA (0.58)
SCHEMBL21583073 0.66 KDM4E (0.60) LMNAKDM4ERAB9AGAAALDH1A1
SCHEMBL25010321 0.66 PTPN7 (0.61) MAPTLMNATHRBKDM4ERAB9A
SCHEMBL27929203 0.65 KMT2A (0.64) MAPTLMNATP53KDM4ERAB9A
SCHEMBL12462826 0.65 MTOR (0.48) PDGFRBKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249129-B2 Morpholino substituted urea derivatives as mTOR inhibitors CELLZOME LIMITED (GB) 2016-02-02 US disclosed
EP-2542536-B1 Morpholino substituted urea derivatives as mtor inhibitors CELLZOME LTD (GB) 2015-01-21 EP disclosed
US-20130196982-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS CELLZOME LIMITED (GB) 2013-08-01 US disclosed
EP-2542536-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS Cellzome Limited (GB) 2013-01-09 EP disclosed
WO-2011107585-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS CELLZOME LIMITED (GB) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196982-A1 MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS MTOR, EIF4E, EIF4A1 MAPT 1704/4885LMNA 1924/4885TP53 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.